Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (1-10 of 275) with videos related to

Pageof 28
Sort By:
Lung Cancer (Amsterdam, Netherlands)|March 28, 2008
EGFR FISH versus mutation: different tests, different end-pointsFederico Cappuzzo
Expert Opinion on Therapeutic Targets|November 16, 2006
Should every lung cancer patient be tested for EGFR mutation?Federico Cappuzzo
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|November 6, 2002
Medical treatment of brain metastases from lung cancerFederico Cappuzzo
Journal of the National Cancer Institute|June 16, 2005
Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?Federico Cappuzzo
Drugs|June 21, 2012
Management of non-small cell lung cancer: focus on erlotinib. ForewordFederico Cappuzzo
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 26, 2007
Predictive factors for response and for resistance to tyrosine kinase inhibitor therapy in lung cancerFederico Cappuzzo
Expert Opinion on Emerging Drugs|August 22, 2009
Emerging drugs for small-cell lung cancerGiulio Metro, Federico Cappuzzo
Translational Lung Cancer Research|February 3, 2017
Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLCLorenza Landi, Federico Cappuzzo
Expert Review of Anticancer Therapy|April 27, 2013
Erlotinib in the first-line treatment of non-small-cell lung cancerManolo D'Arcangelo, Federico Cappuzzo
Expert Review of Clinical Pharmacology|November 20, 2015
Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancerLorenza Landi, Federico Cappuzzo
Pageof 28

Showing results (1-10 of 275) with videos related to

Sort By:
Pageof 28
Lung Cancer (Amsterdam, Netherlands)|March 28, 2008
EGFR FISH versus mutation: different tests, different end-pointsFederico Cappuzzo
Expert Opinion on Therapeutic Targets|November 16, 2006
Should every lung cancer patient be tested for EGFR mutation?Federico Cappuzzo
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|November 6, 2002
Medical treatment of brain metastases from lung cancerFederico Cappuzzo
Journal of the National Cancer Institute|June 16, 2005
Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?Federico Cappuzzo
Drugs|June 21, 2012
Management of non-small cell lung cancer: focus on erlotinib. ForewordFederico Cappuzzo
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 26, 2007
Predictive factors for response and for resistance to tyrosine kinase inhibitor therapy in lung cancerFederico Cappuzzo
Expert Opinion on Emerging Drugs|August 22, 2009
Emerging drugs for small-cell lung cancerGiulio Metro, Federico Cappuzzo
Translational Lung Cancer Research|February 3, 2017
Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLCLorenza Landi, Federico Cappuzzo
Expert Review of Anticancer Therapy|April 27, 2013
Erlotinib in the first-line treatment of non-small-cell lung cancerManolo D'Arcangelo, Federico Cappuzzo
Expert Review of Clinical Pharmacology|November 20, 2015
Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancerLorenza Landi, Federico Cappuzzo
Pageof 28